Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases. It seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Its platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies.
Forge Biologics is a gene therapy development engine, focused on enabling access to life-changing gene therapies and helping bring them from an idea into reality. The company partners with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. It was founded in 2020 and headquartered in Grove City, Ohio.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases. It seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Its platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies.
Biomea Fusion is a privately held precision medicine company with a mission to revolutionize drug development to create more effective therapies for cancer patients. Biomea Fusion has a development portfolio that targets specific gene alterations which occur in the DNA of patients that translate into key drivers of tumor growth. It is Biomea’s goal to move these potentially breakthrough medicines swiftly through the development process and deliver highly impactful treatments for patients in need. The lead program targets the protein-to-protein interaction between menin and the MLL complex for the treatment of various tumors.
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life of patients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting. The company was founded in 2014 and is headquartered in San Diego, California.
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. Its rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond.
Elevation Oncology makes genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Its lead candidate, seribantumab, which inhibits tumor growth driven by NRG1 fusions, is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion.
Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system. The company is driven by a mission to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.
Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology. It engages in treating patients with the most difficult-to-treat cancers for which conventional therapies have failed.
Ajax Health accelerates medical innovation through capital and capabilities.
Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics for patients with high unmet medical needs. The company develops a pipeline of autologous and allogeneic chimeric antigen receptor T cell or CAR-T, product candidates focusing on the treatment of hematological malignancies and solid tumors.
Ajax Health accelerates medical innovation through capital and capabilities.
BridgeBio is a biotechnology company dedicated to the discovery, development, and delivery of medicines for genetic diseases. The company has a diverse pipeline of 20 development programs, which range from early discovery to late-stage clinical trials. Among its notable candidates are BBP-265, an oral small molecule targeting transthyretin amyloidosis currently in Phase 3 trials, and infigratinib, a selective tyrosine kinase inhibitor aimed at treating FGFR-driven cancers and achondroplasia. Additionally, BridgeBio is developing BBP-631, a preclinical gene therapy for congenital adrenal hyperplasia, and BBP-454, a program focused on small molecule inhibitors for KRAS-driven cancers. The company collaborates with several prestigious institutions, including Stanford University and Johns Hopkins University, to enhance its research and development efforts. Founded in 2015 and headquartered in Palo Alto, California, BridgeBio aims to accelerate the development of therapies for Mendelian diseases, genetic dermatology, and oncology.
Atreca is a biopharmaceutical that develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. Its product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discovery platform.
Ajax Health accelerates medical innovation through capital and capabilities.
BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat disease at its source.
Zosano Pharma focuses on creating better products with its innovative drug delivery technology. Zosano's objective is to discover and develop therapeutic drug candidates that address large unmet medical needs or have a significant potential for commercialization. It was founded in 2006 and headquartered in Fremont, California.
Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. The catalyst for creating Avrobio is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to cure serious debilitating disease. Avrobio was founded by industry leaders with unmatched scientific, business, and manufacturing expertise in the field of cell and gene therapy.
ObsEva SA is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine. ObsEva's main focus is on therapies for preterm labor. ObsEva was founded in November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in diverse positions in the biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA.
GTx, Inc. is a company of pioneering and driven individuals who are delivering better medicines with new science through established pathways.
BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.
VYNE Therapeutics is a clinical late-stage biopharmaceutical company that focuses on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis, and prurigo nodularis.
Promentis Pharmaceuticals discovers, develops, and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. Promentis Pharmaceuticals was founded in 2006 and is based in Milwaukee, Wisconsin.
Ajax Health accelerates medical innovation through capital and capabilities.
Prolacta Bioscience, Inc. (www.prolacta.com) is a life science company founded by serial entrepreneur, Elena Medo who has dedicated her career to improving quality of life for sick infants by Advancing the Science of Human MilkTM. Prolacta creates specialty formulations made exclusively from human milk for the nutritional needs of critically ill, premature infants in neonatal intensive care units. It is the first and only company to provide a human milk fortifier made from 100% human milk, Prolact+ H2MF. They operate a pharmaceutical grade processing plant and have designed and patented processes that enable them to make their one-of-a-kind life saving products. Prolacta is committed to making a meaningful difference in the lives of the most vulnerable infants through world-class research and innovative products.
Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough. The company creates therapies to address unmet medical requirements in the treatment of respiratory disorders. Verona Pharma was established in 2005 by Clive Page in London, England.
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss. The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.
Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.
Miramar Labs develops medical devices for aesthetic indications that treat primary axillary (underarm) hyperhidrosis in adults. The miraDry System cannot be used to treat hyperhidrosis elsewhere on the body, including the hands and feet. It was founded in 2006 and is based in Sunnyvale, California.
PowerVision is a private company focused on developing a novel accommodating intraocular lens, which is designed to restore True AccommodationTM. Their innovative FluidVisionTM accommodating intraocular lens (IOL) is poised to help individuals affected by presbyopia and/or cataracts regain the ability to dynamically adjust focus for clear vision at all distances. Fifty years ago, vision correction surgery was changed forever by the invention of the intraocular lens, which is used to treat a cataract – a clouding and hardening of the dime-sized, normally clear, crystalline lens inside your eye which can rob you of your vision in your 60’s, 70’s and 80’s. PowerVision set out to dramatically improve vision correction surgery again. They began the development of their FluidVision IOL, which mimics the way a healthy eye works and can restore clear vision at all distances, near, far, and everywhere in between. It uses a tiny amount of fluid inside the lens and natural eye muscles to change shape and adjust focus just the way your healthy eye does. For the more than 20 million people with cataracts in the U.S. and, ultimately, the more than 90 million with Presbyopia – the loss of ability to focus up close that affects people in their 40’s and 50’s – the FluidVision lens can potentially give them freedom from ever needing glasses, contacts or any vision correction procedure again.
Zavante is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.
Spirox is a California-based medical device company improving the quality of life for patients suffering from nasal obstruction. They are formerly known as Nasoform. Their first product, the LATERA absorbable nasal implant is designed to address one of the most common, yet undertreated, causes of nasal obstruction today, nasal valve collapse (NVC). The company intends to use the funds to complete development, seek US marketing authorization, and initiate product commercialization. Spirox was founded in 2011 and is headquartered in Menlo Park, California.
Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery. The company was incorporated in 2004 and is based in Cleveland, Ohio.
Spirox is a California-based medical device company improving the quality of life for patients suffering from nasal obstruction. They are formerly known as Nasoform. Their first product, the LATERA absorbable nasal implant is designed to address one of the most common, yet undertreated, causes of nasal obstruction today, nasal valve collapse (NVC). The company intends to use the funds to complete development, seek US marketing authorization, and initiate product commercialization. Spirox was founded in 2011 and is headquartered in Menlo Park, California.
Cynapsus is a pharmaceutical company that focuses on developing a non-injectable drug for Parkinson’s disease. The company specializes in the fields of healthcare, biotechnology, pharmaceutical, and therapeutics. It was founded in 2004 and headquartered in Toronto, Ontario.
Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.
Cidara Therapeutics is a biotechnology company that specializes in the fields of healthcare and therapeutics. The company focuses on developing innovative therapies to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. Cidara Therapeutics was founded in 2012 and headquartered in San Diego, California.
Agile Therapeutics is a specialty pharmaceutical company that engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinylestradiol. This is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.
Private Equity Round in 2015
LENSAR offers femtosecond laser technology for refractive cataract surgery, continues to focus on astigmatism, and supports the pursuit of possible results for patients with its Streamline® IV system upgrade. Unique to the LENSAR Laser System, Streamline IV includes various enhancements that offer cataract surgeons advanced adaptation and customization for treatment planning and other essential steps of the cataract surgery procedure with the highest levels of precision, accuracy, and efficiency. To help surgeons confidently manage astigmatism and optimize refractive outcomes for both toric IOLs and arcuate incisions, the LENSAR Laser with Streamline IV has incorporated extreme treatment planning insights. This includes quick and easy patient docking, as well as superior imaging capabilities with LENSAR’s proprietary Augmented Reality™ 3-D model. This technology facilitates enhanced procedure outcomes by adapting individualized treatment plans including precise laser delivery and efficient lens fragmentation that can reduce, and potentially eliminate, the amount of ultrasonic energy delivered into the eye. Additionally, the IntelliAxis Refractive Capsulorhexis® feature provides another dimension of accuracy with biomechanically stable, steep axis markings that help guide precise toric IOL alignment. The marks remain visible postoperatively to help identify any rotation and guide the realignment of the toric IOL to its optimal position. IntelliAxis Refractive Capsulorhexis also incorporates the wireless transfer of preoperative diagnostics from the Cassini® Corneal Shape Analyzer and Pentacam® to help eliminate transcription errors, save time, and guide more confident astigmatism correction. Iris registration further contributes to the system’s accuracy by comparing a pre-op image taken while the eye is docked and adaptively compensates for cyclo rotation for confidence incision placement. LENSAR has recently expanded the platform’s capabilities to include the creation of micro radial incisions that allow surgeons to treat additional corneal conditions post-cataract surgery and support presbyopia inlay procedures. Building on the strength of LENSAR’s foundational femtosecond cataract laser platform, the LENSAR Laser with Streamline IV simplifies practice and surgical workflows while also revolutionizing a surgeon’s ability to deliver optimal outcomes for astigmatic patients.
Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Miramar Labs develops medical devices for aesthetic indications that treat primary axillary (underarm) hyperhidrosis in adults. The miraDry System cannot be used to treat hyperhidrosis elsewhere on the body, including the hands and feet. It was founded in 2006 and is based in Sunnyvale, California.
Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira’s portfolio of five product candidates targets significant market opportunities. It was founded in 2010 and headquartered in Menlo Park, California.
Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the phase 3 trials planned in ABSSSI and CABP.
Cidara Therapeutics is a biotechnology company that specializes in the fields of healthcare and therapeutics. The company focuses on developing innovative therapies to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. Cidara Therapeutics was founded in 2012 and headquartered in San Diego, California.
PowerVision is a private company focused on developing a novel accommodating intraocular lens, which is designed to restore True AccommodationTM. Their innovative FluidVisionTM accommodating intraocular lens (IOL) is poised to help individuals affected by presbyopia and/or cataracts regain the ability to dynamically adjust focus for clear vision at all distances. Fifty years ago, vision correction surgery was changed forever by the invention of the intraocular lens, which is used to treat a cataract – a clouding and hardening of the dime-sized, normally clear, crystalline lens inside your eye which can rob you of your vision in your 60’s, 70’s and 80’s. PowerVision set out to dramatically improve vision correction surgery again. They began the development of their FluidVision IOL, which mimics the way a healthy eye works and can restore clear vision at all distances, near, far, and everywhere in between. It uses a tiny amount of fluid inside the lens and natural eye muscles to change shape and adjust focus just the way your healthy eye does. For the more than 20 million people with cataracts in the U.S. and, ultimately, the more than 90 million with Presbyopia – the loss of ability to focus up close that affects people in their 40’s and 50’s – the FluidVision lens can potentially give them freedom from ever needing glasses, contacts or any vision correction procedure again.
Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, M.D., a partner at Aisling Capital. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for outsized clinical effects in genetically defined patient populations. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery. It is an exciting time to develop cancer drugs. Diagnostic methods are yielding strong clues about which cancer features are actionable, “driver mutations,” in contrast to those merely along for the ride as “passenger mutations.” In the last five years, these insights have transformed the standard of care in melanoma, lung cancer and other cancers. Picking a target is just the first step in building a cancer drug. Good chemists build good drugs. The physical properties of a compound have much to do with its ultimate success or failure. Is it stable? Is it soluble? Is it absorbed? Does it reach its target? Does it engage the target? Does it cause toxicity elsewhere in the body before it achieves maximum efficacy in the cancer? In our opinion, drugs that achieve excellent exposure in the body and are highly specific for their intended targets have the highest chances of success. Once an attractive target is selected and a drug with best-in-class properties is constructed, setting up the right clinical development plan is of utmost importance. Our goal is to generate a clinical path that reflects the underlying scientific hypothesis that made the drug interesting in the first place. This often means developing the drug in a population of patients whose tumors possess a specific genetic vulnerability targeted by the drug. Loxo Oncology was built around a team of full-time professionals and engaged scientific advisors who are aligned in choosing the most actionable targets, and pursuing them through disciplined clinical trial approaches. Our license and collaboration agreement with Array Biopharma and our experienced team allows us to construct drugs with best-in-class properties from the ground up.
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss. The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery. The company was incorporated in 2004 and is based in Cleveland, Ohio.
Seragon Pharmaceuticals, Inc., headquartered in Irvine, California, is a research-based biopharmaceutical company dedicated to improving human and animal health through innovative science. Seragon Pharmaceuticals is committed to applying cutting-edge scientific and technological advancements to the fields of metabolism, gene therapy and bioinformatics. From the research end to consumer products and clinical applications, Seragon strives to bring people access to the most significant breakthroughs in medicine. For more information, please visit www.seragon.com
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, M.D., a partner at Aisling Capital. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for outsized clinical effects in genetically defined patient populations. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery. It is an exciting time to develop cancer drugs. Diagnostic methods are yielding strong clues about which cancer features are actionable, “driver mutations,” in contrast to those merely along for the ride as “passenger mutations.” In the last five years, these insights have transformed the standard of care in melanoma, lung cancer and other cancers. Picking a target is just the first step in building a cancer drug. Good chemists build good drugs. The physical properties of a compound have much to do with its ultimate success or failure. Is it stable? Is it soluble? Is it absorbed? Does it reach its target? Does it engage the target? Does it cause toxicity elsewhere in the body before it achieves maximum efficacy in the cancer? In our opinion, drugs that achieve excellent exposure in the body and are highly specific for their intended targets have the highest chances of success. Once an attractive target is selected and a drug with best-in-class properties is constructed, setting up the right clinical development plan is of utmost importance. Our goal is to generate a clinical path that reflects the underlying scientific hypothesis that made the drug interesting in the first place. This often means developing the drug in a population of patients whose tumors possess a specific genetic vulnerability targeted by the drug. Loxo Oncology was built around a team of full-time professionals and engaged scientific advisors who are aligned in choosing the most actionable targets, and pursuing them through disciplined clinical trial approaches. Our license and collaboration agreement with Array Biopharma and our experienced team allows us to construct drugs with best-in-class properties from the ground up.
Private Equity Round in 2013
LENSAR offers femtosecond laser technology for refractive cataract surgery, continues to focus on astigmatism, and supports the pursuit of possible results for patients with its Streamline® IV system upgrade. Unique to the LENSAR Laser System, Streamline IV includes various enhancements that offer cataract surgeons advanced adaptation and customization for treatment planning and other essential steps of the cataract surgery procedure with the highest levels of precision, accuracy, and efficiency. To help surgeons confidently manage astigmatism and optimize refractive outcomes for both toric IOLs and arcuate incisions, the LENSAR Laser with Streamline IV has incorporated extreme treatment planning insights. This includes quick and easy patient docking, as well as superior imaging capabilities with LENSAR’s proprietary Augmented Reality™ 3-D model. This technology facilitates enhanced procedure outcomes by adapting individualized treatment plans including precise laser delivery and efficient lens fragmentation that can reduce, and potentially eliminate, the amount of ultrasonic energy delivered into the eye. Additionally, the IntelliAxis Refractive Capsulorhexis® feature provides another dimension of accuracy with biomechanically stable, steep axis markings that help guide precise toric IOL alignment. The marks remain visible postoperatively to help identify any rotation and guide the realignment of the toric IOL to its optimal position. IntelliAxis Refractive Capsulorhexis also incorporates the wireless transfer of preoperative diagnostics from the Cassini® Corneal Shape Analyzer and Pentacam® to help eliminate transcription errors, save time, and guide more confident astigmatism correction. Iris registration further contributes to the system’s accuracy by comparing a pre-op image taken while the eye is docked and adaptively compensates for cyclo rotation for confidence incision placement. LENSAR has recently expanded the platform’s capabilities to include the creation of micro radial incisions that allow surgeons to treat additional corneal conditions post-cataract surgery and support presbyopia inlay procedures. Building on the strength of LENSAR’s foundational femtosecond cataract laser platform, the LENSAR Laser with Streamline IV simplifies practice and surgical workflows while also revolutionizing a surgeon’s ability to deliver optimal outcomes for astigmatic patients.
LENSAR offers femtosecond laser technology for refractive cataract surgery, continues to focus on astigmatism, and supports the pursuit of possible results for patients with its Streamline® IV system upgrade. Unique to the LENSAR Laser System, Streamline IV includes various enhancements that offer cataract surgeons advanced adaptation and customization for treatment planning and other essential steps of the cataract surgery procedure with the highest levels of precision, accuracy, and efficiency. To help surgeons confidently manage astigmatism and optimize refractive outcomes for both toric IOLs and arcuate incisions, the LENSAR Laser with Streamline IV has incorporated extreme treatment planning insights. This includes quick and easy patient docking, as well as superior imaging capabilities with LENSAR’s proprietary Augmented Reality™ 3-D model. This technology facilitates enhanced procedure outcomes by adapting individualized treatment plans including precise laser delivery and efficient lens fragmentation that can reduce, and potentially eliminate, the amount of ultrasonic energy delivered into the eye. Additionally, the IntelliAxis Refractive Capsulorhexis® feature provides another dimension of accuracy with biomechanically stable, steep axis markings that help guide precise toric IOL alignment. The marks remain visible postoperatively to help identify any rotation and guide the realignment of the toric IOL to its optimal position. IntelliAxis Refractive Capsulorhexis also incorporates the wireless transfer of preoperative diagnostics from the Cassini® Corneal Shape Analyzer and Pentacam® to help eliminate transcription errors, save time, and guide more confident astigmatism correction. Iris registration further contributes to the system’s accuracy by comparing a pre-op image taken while the eye is docked and adaptively compensates for cyclo rotation for confidence incision placement. LENSAR has recently expanded the platform’s capabilities to include the creation of micro radial incisions that allow surgeons to treat additional corneal conditions post-cataract surgery and support presbyopia inlay procedures. Building on the strength of LENSAR’s foundational femtosecond cataract laser platform, the LENSAR Laser with Streamline IV simplifies practice and surgical workflows while also revolutionizing a surgeon’s ability to deliver optimal outcomes for astigmatic patients.
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
Private Equity Round in 2013
TRIA Beauty develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers.
ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery. The company was incorporated in 2004 and is based in Cleveland, Ohio.
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.
T2 Biosystems is a private company developing a next-generation medical diagnostic platform that enables rapid and accurate diagnostic tests of all types on a single, easy-to-use instrument. The company's proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time-consuming sample preparation.
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.
Aragon Pharmaceuticals is a discovery-stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.
TRIA Beauty develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers.
Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases
Agile Therapeutics is a specialty pharmaceutical company that engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinylestradiol. This is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.
PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities.
Cytos is a public biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform.
ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery. The company was incorporated in 2004 and is based in Cleveland, Ohio.
LENSAR offers femtosecond laser technology for refractive cataract surgery, continues to focus on astigmatism, and supports the pursuit of possible results for patients with its Streamline® IV system upgrade. Unique to the LENSAR Laser System, Streamline IV includes various enhancements that offer cataract surgeons advanced adaptation and customization for treatment planning and other essential steps of the cataract surgery procedure with the highest levels of precision, accuracy, and efficiency. To help surgeons confidently manage astigmatism and optimize refractive outcomes for both toric IOLs and arcuate incisions, the LENSAR Laser with Streamline IV has incorporated extreme treatment planning insights. This includes quick and easy patient docking, as well as superior imaging capabilities with LENSAR’s proprietary Augmented Reality™ 3-D model. This technology facilitates enhanced procedure outcomes by adapting individualized treatment plans including precise laser delivery and efficient lens fragmentation that can reduce, and potentially eliminate, the amount of ultrasonic energy delivered into the eye. Additionally, the IntelliAxis Refractive Capsulorhexis® feature provides another dimension of accuracy with biomechanically stable, steep axis markings that help guide precise toric IOL alignment. The marks remain visible postoperatively to help identify any rotation and guide the realignment of the toric IOL to its optimal position. IntelliAxis Refractive Capsulorhexis also incorporates the wireless transfer of preoperative diagnostics from the Cassini® Corneal Shape Analyzer and Pentacam® to help eliminate transcription errors, save time, and guide more confident astigmatism correction. Iris registration further contributes to the system’s accuracy by comparing a pre-op image taken while the eye is docked and adaptively compensates for cyclo rotation for confidence incision placement. LENSAR has recently expanded the platform’s capabilities to include the creation of micro radial incisions that allow surgeons to treat additional corneal conditions post-cataract surgery and support presbyopia inlay procedures. Building on the strength of LENSAR’s foundational femtosecond cataract laser platform, the LENSAR Laser with Streamline IV simplifies practice and surgical workflows while also revolutionizing a surgeon’s ability to deliver optimal outcomes for astigmatic patients.
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002.
CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.
Roka Bioscience is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the Food Safety Industry. Its newly released Atlas System represents a new tier of molecular rapid pathogen testing, offering automation and technology that bring true walk-away convenience and workflow advantages to the laboratory. Roka is focused on creating novel testing solutions that help manufacturers mitigate risks, protect their brands, and meet the increasing testing demands now and for years to come.
ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery. The company was incorporated in 2004 and is based in Cleveland, Ohio.
T2 Biosystems is a private company developing a next-generation medical diagnostic platform that enables rapid and accurate diagnostic tests of all types on a single, easy-to-use instrument. The company's proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time-consuming sample preparation.
Pharmaron provides research, development, and manufacturing services throughout the drug discovery, preclinical, and clinical development processes across therapeutic modalities, including small molecules, biologics, and CGT products. Their services include laboratory chemistry, biosciences, chemistry, manufacturing, safety assessment, clinical development, and drug discovery services.
TRIA Beauty develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers.
NextWave Pharmaceuticals, a Cupertino, CA-based pharmaceutical company that develops and commercializes products utilizing proprietary drug delivery technology.
ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery. The company was incorporated in 2004 and is based in Cleveland, Ohio.
Zeltiq (pronounced Zel ′teek) Aesthetics, founded in 2005, is a science-based medical device company dedicated to the development of non-invasive procedures for the reduction of unwanted fat tissue. The Zeltiq approach utilizes a patented method called Cryolipolysis™ (the use of precisely controlled cooling to remove fat) that is designed to target only fat cells and not harm the skin or other tissue. The Zeltiq device is cleared by the FDA in the Unites States for various applications related to skin cooling during dermatologic treatments.
Aragon Pharmaceuticals is a discovery-stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.
Asensus Surgical is a digital interface between the surgeon and patient to improve minimally invasive surgery through digital laparoscopy. They enable capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seek to address the current clinical, cognitive, and economic shortcomings in surgery.
Cempra seeks to discover and develop well-differentiated medicines that cure bacterial infections and improve the quality of life for those with chronic illnesses. The company balances near-term product development opportunities, including the macrolide CEM-101, while investing in future products from new technologies to derive the next generation of antibiotics.
Bridge Pharmaceuticals is a drug development research organization based in Gaithersburg, Maryland. It provides toxicology and pharmacology services to support investigational new drug applications on a global scale.
TRIA Beauty develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers.
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.
ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery. The company was incorporated in 2004 and is based in Cleveland, Ohio.
Sanofi-Topaz (formerly Topaz Pharmaceuticals) develops and manufactures pharmaceutical products for children’s health issues. It provides various drugs for the treatment of head lice, acne, and infections, as well as vaccines against childhood diseases. Sanofi-Topaz was founded in 2005 and is headquartered in Horsham, Pennsylvania.
Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the phase 3 trials planned in ABSSSI and CABP.
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.
Cempra seeks to discover and develop well-differentiated medicines that cure bacterial infections and improve the quality of life for those with chronic illnesses. The company balances near-term product development opportunities, including the macrolide CEM-101, while investing in future products from new technologies to derive the next generation of antibiotics.
BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.
Bioenvision a biopharmaceutical company, engages in the acquisition, development, and marketing of compounds and technologies primarily for the treatment of cancer. Its lead products include Evoltra (clofarabine) which has marketing approval in both the European Union and United States for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia and Modrenal (trilostane), which has marketing approval in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy.
As of February 23, 2010, The Natural Dentist, Inc. was acquired by Revive Personal Products Company. The company manufactures oral care products in the United States. It offers mouth rinses and toothpastes through stores and online retailers, as well as through phone. The company was formerly known as Woodstock Natural Products Inc and changed its name to The Natural Dentist, Inc. in 2005. The Natural Dentist, Inc. was founded in 1995 and is based in Medford, Massachusetts.
Sirion Therapeutics is a biopharmaceutical company, engaged in developing, and commercializing of products for the protection of eyesight.
Cempra seeks to discover and develop well-differentiated medicines that cure bacterial infections and improve the quality of life for those with chronic illnesses. The company balances near-term product development opportunities, including the macrolide CEM-101, while investing in future products from new technologies to derive the next generation of antibiotics.
Cardiokine, Inc., a specialty pharmaceutical company, engages in the development of pharmaceuticals for the prevention and treatment of cardiovascular diseases. Its products include lixivaptan, an orally active vasopressin receptor antagonist for patients with congestive heart failure who suffer from hyponatremia. The company was founded in 2004 and is headquartered in Philadelphia, Pennsylvania.